Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients

D. J. Wojenski, G. T. Bartoo, J. A. Merten, R. A. Dierkhising, M. R. Barajas, R. A. el-Azhary, J. W. Wilson, M. F. Plevak, W. J. Hogan, M. R. Litzow, M. M. Patnaik, R. C. Wolf, S. K. Hashmi

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background: Voriconazole is a commonly used antifungal medication in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients. In solid organ transplantation, voriconazole use has been associated with the development of cutaneous squamous cell carcinoma (SCC). We sought to determine if voriconazole use was associated with SCC in patients undergoing allo-HSCT. Methods: We retrospectively reviewed consecutive adult patients who underwent allo-HSCT at Mayo Clinic from January 2007 through July 2012. Multivariable Cox models were created to assess the relationship of SCC with two time-dependent voriconazole exposure variables: (i) history of voriconazole exposure (yes/no), and (ii) cumulative days of voriconazole use. Results: In our cohort of 381 allo-HSCT patients, SCC developed in 26 of 312 patients exposed to voriconazole (25 post-voriconazole) and in 1 of 69 patients who received alternative antifungal agent(s). Cumulative incidence of SCC was estimated to be 19% at 5 years post allo-transplant. Cumulative days of voriconazole use was found to be a risk factor for SCC, and this relationship persisted in a multivariable model using previously identified risk factors as covariates (hazard ratio 1.859 for each 180 days of use, P < 0.001). Conclusion: This is the first study, to our knowledge, to identify cumulative days of voriconazole use as a risk factor for SCC development following allo-HSCT, and may help guide appropriate antifungal use in this patient population.

Original languageEnglish (US)
Pages (from-to)250-258
Number of pages9
JournalTransplant Infectious Disease
Volume17
Issue number2
DOIs
StatePublished - Apr 1 2015

Keywords

  • Cutaneous squamous cell carcinoma
  • Hematopoietic stem cell transplantation
  • Immunocompromised host
  • Triazole adverse effects
  • Voriconazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation

Fingerprint Dive into the research topics of 'Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients'. Together they form a unique fingerprint.

  • Cite this

    Wojenski, D. J., Bartoo, G. T., Merten, J. A., Dierkhising, R. A., Barajas, M. R., el-Azhary, R. A., Wilson, J. W., Plevak, M. F., Hogan, W. J., Litzow, M. R., Patnaik, M. M., Wolf, R. C., & Hashmi, S. K. (2015). Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transplant Infectious Disease, 17(2), 250-258. https://doi.org/10.1111/tid.12367